How Continuous Glucose Monitoring Can Benefit MDI Patients

Multiple studies\(^1\)\(^-\)\(^7\) have demonstrated the clinical benefits of CGM. Regardless of how insulin is administered, patients on insulin injections can benefit from CGM no matter which MDI regimen is prescribed.

### Meet Jake\(^*\)

- 32 year old with T1 diabetes for 12 years
- A1C is 7.8%; Has ICR of 1:15 and CF of 1:50
- Exercises 3-4 times/week; Has some hypoglycemia (~2x/week)
- Tries to take care of his diabetes; desires good control
- Tests his blood sugar 4-6x/day
- Refuses to be on pump; tried CGM when newly diagnosed but wasn’t impressed with it

\(^*\)Hypothetical patient profile, for training purposes only.

**Insulin Carb Ratio (ICR) and Correction Factor (CF) Dosing Regimen**

**Candidates To Consider:**
- Both Type 1 and Type 2 patients
- Any MDI patient with hypoglycemia
- Any MDI patient not at A1C goal
- Any MDI patient with glycemic variability

### How CGM benefits Patients on ICR+CF Dosing Regimen

- View continuous and timely feedback on diet, exercise, and insulin requirements to help make informed diabetes management decisions
- Help reduce hypoglycemic and hyperglycemic events and increase time in glucose target range\(^8\)
- Help reduce A1C without increasing hypoglycemia, glucose variability and fluctuations\(^9\)
BRIEF SAFETY STATEMENT
The Dexcom G5 Mobile Continuous Glucose Monitoring System is a glucose monitoring system indicated for detecting trends and tracking patterns in persons (age 2 years and older) with diabetes. CONTRAINDICATIONS Remove the System before MRI, CT scan, or diathermy treatment. The device is MR Unsafe. Do not bring any portion of the System into the MR environment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings.WARNIMG Do not use the System for treatment decisions. The System does not replace a blood glucose meter. The System is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). Your smart device’s internal settings override your app settings. Accessory devices (like a smart watch) might override your smart device’s alert and notification settings. The Share feature must be turned “On” with an active internet connection to communicate glucose information to a Follower. The Follower must download and install the Dexcom Follow App onto a separate smart device with an active internet connection to receive data. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

©2016 Dexcom Inc. All rights reserved.

References: